viewGSRX Industries Inc.

GSRX Industries, now a unit of Chemesis, posts most quarterly revenue to date

For its second quarter of 2019, GSRX earned nearly $3.5 million in revenue, compared to just $353.430 in the year-ago quarter

Cannabis plant and dollars
Chemesis completed its acquisition of a majority holding in GSRX at the end of August

GSRX Industries Inc (OTCMKTS:GSRX), which is now a subsidiary of Chemesis International Inc. (CSE:CSI) and (OTCMKTS:CADMF), took in its most year-over-year quarterly revenue to date in its second quarter.

In a statement, Chemesis - which completed its acquisition of a majority holding in GSRX at the end of August - said GSRX earned nearly $3.5 million in revenue in its second quarter, compared to just $353.430 in the year-ago quarter. 

It said GSRX also produced a gross profit of US$1.34 million and a gross margin of 39%.

READ: GSRX Industries Inc and Chemesis International Inc progress towards deal to create fully integrated multistate operator

The cannabis company also saw a narrowing loss of about $924,000 in the second quarter, compared to a $3.6 million loss in the prior-year quarter. It said the revenue growth was primarily achieved through its retail business’ in Puerto Rico, California, Texas, and Tennessee. 

GSRX currently operates six dispensaries and two retail CBD stores, as well as five pre-qualified dispensaries in Puerto Rico that are in various stages of development. It also has a dispensary in Palm Springs, California.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: GSRX Industries Inc.

Price: 0.05 USD

Market: OTCQB
Market Cap: $4.09 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of GSRX Industries Inc. named herein, including the promotion by the Company of GSRX Industries Inc. in any Content on the Site, the Company...



Amryt Pharma releases Q-2 financials that show strong revenue growth as...

Amryt Pharma (Nasdaq: AMYT) CEO Dr Joe Wiley joined Steve Darling from Proactive with news the company saw a nice increase in revenue as they released their Q-2 numbers. Dr Wiley talked about some of the numbers and what was driving that revenue. Wiley also told Proactive the company has, for...

12 hours, 11 minutes ago

2 min read